168 related articles for article (PubMed ID: 27788210)
1. Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer.
Fedoseienko A; Wieringa HW; Wisman GB; Duiker E; Reyners AK; Hofker MH; van der Zee AG; van de Sluis B; van Vugt MA
PLoS One; 2016; 11(10):e0165385. PubMed ID: 27788210
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
3. PMS2 expression in epithelial ovarian cancer is posttranslationally regulated by Akt and essential for platinum-induced apoptosis.
Jia J; Wang Z; Cai J; Zhang Y
Tumour Biol; 2016 Mar; 37(3):3059-69. PubMed ID: 26423401
[TBL] [Abstract][Full Text] [Related]
4. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
5. Theaflavin-3, 3'-digallate induces apoptosis and G2 cell cycle arrest through the Akt/MDM2/p53 pathway in cisplatin-resistant ovarian cancer A2780/CP70 cells.
Tu Y; Kim E; Gao Y; Rankin GO; Li B; Chen YC
Int J Oncol; 2016 Jun; 48(6):2657-65. PubMed ID: 27082635
[TBL] [Abstract][Full Text] [Related]
6. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
7. [Influence of mifepristone on DNA repair genes and cisplatin sensitivity in human ovarian cancer drug-resistance cells].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):132-5. PubMed ID: 18683754
[TBL] [Abstract][Full Text] [Related]
8. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
10. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
Yan X; Fraser M; Qiu Q; Tsang BK
Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
[TBL] [Abstract][Full Text] [Related]
11. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
Sun C; Li N; Yang Z; Zhou B; He Y; Weng D; Fang Y; Wu P; Chen P; Yang X; Ma D; Zhou J; Chen G
J Natl Cancer Inst; 2013 Nov; 105(22):1750-8. PubMed ID: 24168967
[TBL] [Abstract][Full Text] [Related]
12. RIP1 promotes proliferation through G2/M checkpoint progression and mediates cisplatin-induced apoptosis and necroptosis in human ovarian cancer cells.
Zheng XL; Yang JJ; Wang YY; Li Q; Song YP; Su M; Li JK; Zhang L; Li ZP; Zhou B; Lin Y
Acta Pharmacol Sin; 2020 Sep; 41(9):1223-1233. PubMed ID: 32242118
[TBL] [Abstract][Full Text] [Related]
13. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
[TBL] [Abstract][Full Text] [Related]
14. Effect of histone deacetylase inhibitors on cell apoptosis and expression of the tumor suppressor genes RUNX3 and ARHI in ovarian tumors.
Zhang L; Liu P; Li H; Xue F
Mol Med Rep; 2013 May; 7(5):1705-9. PubMed ID: 23504001
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of Eag1 Expression by RNA Interference Increases Chemosensitivity to Cisplatin in Ovarian Cancer Cells.
Hui C; Lan Z; Yue-li L; Li-lin H; Li-lin H
Reprod Sci; 2015 Dec; 22(12):1618-26. PubMed ID: 26079730
[TBL] [Abstract][Full Text] [Related]
16. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
Zhang Y; Wang J; Xiang D; Wang D; Xin X
Int J Oncol; 2009 Nov; 35(5):1069-79. PubMed ID: 19787261
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin: A Potential Treatment Strategy.
Chiba Y; Sato S; Itamochi H; Yoshino N; Fukagawa D; Kawamura H; Suga Y; Kojima-Chiba A; Muraki Y; Sugai T; Sugiyama T
Int J Gynecol Cancer; 2017 Oct; 27(8):1666-1674. PubMed ID: 28786875
[TBL] [Abstract][Full Text] [Related]
18. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.
Washington MN; Suh G; Orozco AF; Sutton MN; Yang H; Wang Y; Mao W; Millward S; Ornelas A; Atkinson N; Liao W; Bast RC; Lu Z
Cell Death Dis; 2015 Aug; 6(8):e1836. PubMed ID: 26247722
[TBL] [Abstract][Full Text] [Related]
19. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.
Scurr LL; Guminski AD; Chiew YE; Balleine RL; Sharma R; Lei Y; Pryor K; Wain GV; Brand A; Byth K; Kennedy C; Rizos H; Harnett PR; deFazio A
Clin Cancer Res; 2008 Nov; 14(21):6924-32. PubMed ID: 18980987
[TBL] [Abstract][Full Text] [Related]
20. ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome.
Surowiak P; Materna V; Kaplenko I; Spaczynski M; Dolinska-Krajewska B; Gebarowska E; Dietel M; Zabel M; Lage H
Clin Cancer Res; 2006 Dec; 12(23):7149-58. PubMed ID: 17145840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]